Chief Medical and Development Officer · Kyverna Therapeutics, Inc. (KYTX)

Naji Gehchan

FY2025 is the first fiscal year CompBrief holds for Naji Gehchan as a named executive officer of Kyverna Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$2,085,173

Compensation figures as of the proxy filed April 13, 2026 (DEF 14A).

Naji Gehchan compensation by year

Kyverna Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Kyverna Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$481,667
Bonus$250,000
Stock awards$0
Option awards$1,110,100
Non-equity incentive$238,406
Pension and deferred compensation$0
All other$5,000
Total$2,085,173

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kyverna Therapeutics, Inc. DEF 14A filed April 13, 2026, accession 0001193125-26-152835, and prior-year filings. Open the filing on EDGAR.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option425,000—$3.29

Per the Outstanding Equity Awards at Fiscal Year-End table in Kyverna Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Kyverna Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Naji Gehchan · this pageChief Medical and Development Officer$2,085,173
Warner BiddleChief Executive Officer$1,814,980
Marc GrassoChief Financial Officer$1,663,536

The full Kyverna Therapeutics compensation record

free company brief

This page is one person within Kyverna Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Kyverna Therapeutics's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kyverna Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy